Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 5/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781980 | 0.84 | AHR (0.48) | KMOMAPT | |
| SCHEMBL18042052 | 0.79 | DAPK3 (0.46) | KMO | |
| SCHEMBL44172 | 0.77 | METAP2 (0.44) | KMOCASP1MAPT | |
| SCHEMBL2063712 | 0.77 | MPL (0.50) | KMOAR | |
| SCHEMBL4089983 | 0.76 | NTRK1 (0.43) | KMO | |
| SCHEMBL26968315 | 0.76 | EGFR (0.35) | KMOMAPT | |
| SCHEMBL6189936 | 0.76 | EGFR (0.64) | EPHB4 | |
| SCHEMBL16433245 | 0.76 | KDM1A (0.47) | ABL1EPHB4PIK3CA | |
| SCHEMBL6924818 | 0.76 | NOTUM (0.56) | — | |
| SCHEMBL12781975 | 0.75 | IDO1 (0.50) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2358710-A1 | AKT AND P70 S6 KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056563-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | KMO 4311/4885CASP1 4034/4885ERCC1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.